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Effect of cyclosporin A on Immunoglobulin class in patients receiving 
blood transfusions. IgG antibodies detected by flow cytometry in sera 
from potential renal transplant recipients are associated with an in-
creased number of rejection episodes and impaired graft function. 
Furthermore, cytotoxic antibodies may develop if pre-transplant blood 
transfusions are given to such patients. We have investigated the effect 
of cyclosporin A on the development of IgM and IgG antibodies 
detected by flow cytometry after blood transfusions in 16 previously 
untransfused dialysis patients. Eight (group 1) received three to five 
third-party blood transfusions at two weekly intervals and the remain-
ing eight (group 2) received transfusions with concomitant cyclosporin 
A therapy (10 mg/kg/day). Sera obtained after each transfusion were 
tested using flow cytometry against lymphocytes from six normal 
donors. In all 462 serum/cell combinations were tested. Sera from six 
out of eight patients in group 1 showed IgG antibody activity following 
blood transfusions and none developed IgM antibodies alone. In 
contrast IgG antibody activity was detected in one serum sample from 
only one of the eight patients in group 2 (P < 0.02); a further three 
patients developed IgM but not IgG antibody activity during the 
transfusion protocol. IgG antibodies were found in 25/228 serum/cell 
combinations in group 1 but in 11234 in group 2 (P < 0.001). The patient 
in group 2 who developed IgG antibodies in one serum/cell combination 
was known to have red cell autoantibodies. This IgG activity was 
removed by red cell absorption, suggesting that the autoreactive red cell 
antibody cross-reacted with lymphocytes. Cytotoxic antibodies were 
detected in two serum/cell combinations in group 1 alone. We conclude 
that the switch from IgM to IgG antibody production is abrogated by 
cyclosporin A. This may be one mechanism by which cyclosporin A 
prevents the development of cytotoxic antibodies in potential graft 
recipients given third-party blood transfusions. 
Since Opelz et al demonstrated the beneficial effect of blood 
transfusions given before transplantation on renal graft survival 
in 1973 [1], the administration of transfusions to potential graft 
recipients has become routine in many transplantation centers. 
More recently, however, the place of elective blood transfu-
sions has become more controversial [2-5], but a recent large 
study [6] shows a beneficial effect in these where at least one 
HLA-UR antigen was foreign to the recipient. 
Unfortunately blood transfusions can also lead to the devel-
opment of cytotoxic antibodies in sera from potential graft 
recipients. Such antibodies may react with donor lymphocytes 
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causing a positive crossmatch test. If broad reactivity develops 
against lymphocytes from a high percentage of members of a 
normal lymphocyte panel the number of suitable kidney donors 
diminishes markedly. The development of broad sensitization is 
rare after blood transfusions alone but common in patients who 
are transfused after a previous pregnancy [7, 8] or failed 
allograft [9, 10]. The clinical problem of identifying suitable 
donors for the increasing number of sensitized recipients has 
become a potent factor against a policy of pre-transplant blood 
transfusions. The concomitant administration of immunosup-
pressive drugs such as azathioprine [11-13] or cyclosporin A 
[14] with donor specific transfusions [15] or third party transfu-
sions prevented sensitization; cyclosporin A appeared the more 
effective drug [16]. 
Cyclosporin A has previously been shown to abrogate the 
humoral response to T dependent antigens in a rodent model 
[17], and in recent animal studies we have demonstrated that 
cyclosporin A can reduce the initial IgM response to allogenic 
blood transfusion and suppress the subsequent production of 
IgG [18]. 
IgG antibodies against donor lymphocytes detected by the 
standard crossmatch technique are clearly associated with graft 
failure [19, 20]. If, however, the positive crossmatch is due to 
IgM antibodies then successful transplantation is still possible, 
partiCUlarly if the IgM antibodies are autoantibodies [21-23]. 
Lymphocyte binding antibodies can be detected using flow 
cytometry and are associated with a high risk of the patient 
developing broadly reactive cytotoxic antibodies after further 
transfusions [24]. Such antibodies may represent low levels of 
cytotoxic anti-HLA antibodies. If present in pretransplant sera 
they appear to be associated with an increased incidence of 
impaired graft function [25, 26]. Other groups have gone further 
and shown an association between the presence of lymphocyte 
binding IgG antibodies detected against donor lymphocytes 
using flow cytometry and poor graft survival rates [27, 28]. The 
aim of the present study, therefore, is to investigate the effect of 
cyclosporin A on the alloantibody response to third-party blood 
transfusions in potential allograft recipients using flow cytom-
etry. 
Methods 
Patients 
Sixteen previously untransfused dialysis patients were given 
a planned program of third-party transfusions between 1985 and 
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1989. All patients were Caucasian and natives of Scotland. 
Eight patients (group 1) received between 3 and 5 units of blood 
at two weekly intervals. Eight patients (group 2) received 
transfusions with concomitant cyclosporin A (10 mg/kg/day) 
from four days before the first transfusion until one week after 
the last. Two patients in group 1 received one and three 
additional clinically-indicated transfusions. Each group was 
comprised of three women and five men, and one parous 
woman was included in each group. Both women had had two 
pregnancies; none of our patients suffered from systemic lupus 
erythematosus. We have since changed our policy and parous 
women are no longer electively transfused. Blood donors came 
from the North-East of Scotland and hence belonged to the 
same population group as the patients. 
Sera and target cells 
Serum samples, obtained from the 16 patients prior to each 
transfusion and two weeks after the last, were heat inactivated 
at 56°C for 45 minutes, ultracentrifuged at 100,000 x g for 60 
minutes and stored at -70°C until assayed. Mononuclear leu-
cocytes were separated from the blood of six healthy Caucasian 
volunteers, chosen to share HLA antigens common in the 
North-East of Scotland, by centrifugation with Ficoll-Hypaque. 
In all 462 serum/cell combinations were tested. The tissue types 
of the panel members were: (1) A3, B7,18, DR4,w6 (2) Al,2, 
B8,w62(l5), DR3,4 (3) A2,11, B7,44,DR1,7 (4) A3,10(25,26), 
BI5(63),18,DR2,4 (5) A4,wI9, B14,50 DR 1,4 (6) AI,B35, 
w55(22), DR5. These represent over 85% of the HLA A and B 
antigens which occur at a frequency of greater than 10% in the 
blood donor population of North-East Scotland. All HLA DR 
specificities (l to 7) were present in the panel. 
Complement dependent cytotoxicity (CDC) 
The standard long incubation, two-stage NIH microlympho-
cytotoxicity assay was performed using peripheral blood lym-
phocytes [29]. Lymphocytotoxicity was considered positive if 
cell kill was more than 20% above background. 
Flow cytometry 
The presence of lymphocyte antibodies was detected by 
indirect immunofluorescence and flow cytometry. Twenty-five 
microliters of mononuclear cell suspension were incubated with 
25 ILl oftest serum for 30 minutes at 22°C. After two washes the 
cells were resuspended in 25 ILl of a 1 :50 dilution of the F(ab')2 
fragment of a poly specific goat antibody to human immunoglob-
ulins conjugated to fluorescein isothiocyanate (FITC) (T AGO) 
and incubated for 30 minutes ih the dark at 4°C. The cells wer~ 
w~shed twice, resuspended and analyzed by flow cytometry 
usmg an EPICS C flow cytometer. The mean channel of 560 nm 
fluorescence intensity was determined for each test sample 
performed in duplicate. Results obtained were compared with 
the patient's pretransfusion serum and a normal male control 
serum. The test serum was considered positive when the mean 
channel shift was above the 95% confidence limits determined 
by 36 control sera/cell combinations compared with the pa-
tient's pre-transfusion serum. 
Positive serum/cell combinations were subsequently 
screened for antibody activity by incubating each serum cell 
combination in parallel with the polyspecific antihuman FITC 
conjugate, a 1 :20 dilution of goat antihuman IgM FITC conju-
Table 1. Antibodies detected by complement dependent cytotoxicity 
(CDC) and flow cytometry.(FC) during the blood transfusion 
protocol; results expressed as number of positive serum/cell 
combinations 
FC 
Patient total 
Group I 
I 10 
2 2 
3 4 
4 6 
5 2 
6 3 
7 
8 
27 
Group 2 
I 3 
2 3 
3 4 
4 3 
5 
6 
7 
8 
13 
IgM 
2 
2 
2 
6 
3 
3 
4 
10 
IgO 
10 
I 
3 
6 
2 
3 
25 
CDC 
2 
2 
gate (Sigma, Poole, Dorset, UK) and a 1:30 dilution of goat 
antihuman IgG FITC conjugate (Sigma). 
A human IgM monoclonal antibody which binds to lympho-
cytes from all donors (from Dr. A. Ting and Mr. C.J. Taylor, 
Nuffield Department of Surgery, John Radcliffe Hospital, Ox-
ford, UK) and an IgG preparation of serum containing multi-
specific lymphocyte alloantibodies were used as positive con-
trols. The fluorescein conjugated antibodies were shown to be 
specific for the appropriate isotype iri the flow cytometry assay. 
Red cell absorption 
One serum sample which was positive in flow cytoJietry was 
obtained from a patient with previous known red cell autoanti-
bodies. This sample was tested for autoantibodies using the 
sensitive papain layer enzyme technique before and after ab-
sorption with group 0 red cells. Equal volumes of serum, 0.1% 
papain-cystein and a 3 to 5% red cell suspension from each of 
eight normal donors were layered in a precipitin tube and 
incubated for one hour at 37°C. The development of micro-
scopic agglutination was accepted as positive. Simultaneously 
absorbed and unabsorbed sera from three other patients which 
were positive in flow cytometry were screened for the presence 
of red cell autoantibodies. 
Statistical analyses were performed using X- or Fisher's exact 
test. 
Results 
Development of cytotoxic antibodies during the transfusion 
protocol 
Only one patient (No.4 in group 1) developed cytotoxic 
antibodies (Table 1) against two of the six target cells. The 
antibodies developed after the second and third transfusions in 
sera from a woman who had two previous pregnancies. 
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Table i. Time course of IgM and IgG antibody development during 
the blood transfllsion protocol 
Patient BTa lb 
Group 1 
1 8 
2 3 
3 6 
4 3 
5 4 
6 5 
7 5 
8 5 
Group 2 
1 3 
2 5 
3 5 
4 5 IgG 
5 5 
6 4 
7 5 
8 5 
2 
IgG 
IgM 
IgM 
IgM 
3 
IgM/IgG 
IgM 
IgG 
IgG 
IgM 
IgM 
IgM 
4 
IgMlIgG 
IgM/IgG 
IgG 
IgG 
IgM 
IgM 
a Number of administered blood transfusions (BT) 
5 
IgM/IgG 
IgG 
IgG 
IgM 
b Antibody development after blood transfusion 1 respectively 2,3,4,5 
Development of lymphocyte binding antibodies detected by 
flow cytometry 
All 462 serum/cell combinations were screened for lympho-
cyte antibodies by flow cytometry using the poly specific anti-
human immunoglobulin as a secondary antibody. None of the 
patients including the two previously pregnant women devel-
oped antibodies before receiving blood transfusions. Six of 
eight patients in group 1 developed such antibodies in 27 
serum/cell combinations during the transfusion protocol (Table 
1). Only four patients in group 2 developed antibodies which 
were present in 13 of the serum/cell combinations tested. This 
difference in positive serum/cell combinations between the two 
groups was statistically significant (P < 0.02, X2 analysis). 
Development of IgM and IgG antibodies during blood 
transfusion administration 
Six of the eight patients in group 1 developed IgG antibodies 
during the course of the protocol (Table I); IgG activity 
occurred mainly after the third and fourth transfusion (Table 2). 
In one patient the development of IgG antibodies was preceded 
by IgM antibody production (patient 3) indicating that we could 
demonstrate the switch from IgM to IgG antibody production 
following the allogeneic stimulus. In four sera from three 
patients in this group IgM and IgG antibodies were detected. 
Thus both IgM and IgG activity was present in sera from 
patients given blood ttansfusions without cyclosporin A. 
In contrast, three patients in group 2 showed IgM activity in 
their sera during the transfusion protocol (Table 1) and none 
developed activity. Antibodies in these patients developed after 
the second transfusion, that is, earlier than those in group 1 
(Table 2). Thtee positive serum/cell combinations from two 
different patients in this group possessed neither IgM nor IgG 
activity, suggesting that such antibodies might belong to an-
other immunoglobulin class. The IgM antibodies detected did 
not bind to autologous lymphocytes. Only one patient out of 
eight in group 2 who received cyclosporin A along with trans-
fusions developed IgG antibodies, in contrast to six of eight 
patients in group 2. This difference was statistically significant 
(P < 0.02, Fisher's exact test). Furthermore IgG antibodies 
occurred in only one out of 234 serum/cell combinations in 
group 2 but in 25 of228 in group 1 (P < 0.001, ¥ analysis). The 
patient in group 2 who developed IgG antibodies after the first 
transfusion had previously been known to possess IgG red cell 
autoantibodies. After absorption with pooled erythrocytes both 
the red cell and lymphocyte binding IgG antibody activity 
disappeared. In contrast, three sera which contained IgG lym-
phocyte antibodies obtained from patients in group 1 with no 
red cell autoantibodies continued to be active after a similar 
absorption procedure. 
Clinical outcome 
Of the eight patients in group 1, four have received a cadaver 
donor transplant; all grafts failed within two months, and three 
patients developed IgG antibodies during the course of the 
study. In contrast all grafts from the four transplanted patients 
in group 2 are functioning between two and four years after 
transplantation. One of the patients developed IgM antibodies 
during the study, the others showed no detectable antibody 
activity. 
Discussion 
This study shows that cyclosporin A given with allogeneic 
blood transfusions permitted an IgM response to transfUSIon in 
three of eight patients but prevented the switch from IgM to IgG 
production; IgG lymphocyte antibodies were detected only in 
one patient in this group. In contrast, six out of eight patients 
who received transfusions alone developed IgG antibodies. 
The place of elective blood transfusions in the preparation of 
patients for transplantation is one of the main controversies in 
current transplantation research. One study [30] concluded that 
'one year cadaveric graft function in cyclosporin A treated 
patients was independent bf blood transfusion history'. The 
authors, however, did show a significant (P < 0.05) improve-
ment in transplant survival in transfused compared with un-
transfused cyclosporin A treated patients, although the trans-
fusion effect was less than in patients treated with azathioprine 
and prednisolone (P < 0.01). There are difficulties in comparing 
survival rates in the two groups as 77% of patients treated with 
azathioprine and prednisolone were transplanted before those 
given cyclosporin A; the study therefore represents an histori-
cal comparison. Furthermore the proportion of patients in each 
group who received a second or subsequent graft was not 
stated. A multiceriter study of over 15,000 first graft recipients 
transplanted in 1984 and 1985 failed to show a beneficial effect 
of transfusions on graft survival in either cyclosporin A or 
azathioprine and prednisolone treated patients [2]. There were, 
however, only 1033 patients in the untransfused group and over 
14,000 in the transfused group, and the author, Opelz, was 
cautious in interpreting these data. He suggested that non-
transfused recipients might have had higher baseline immuno-
suppression and more aggressive treatment of early rejection. 
Subsequently a study of over 10,000 transplants performed 
between 1984 and 1987 showed a significant improvement in 
overall transplant survival in transfused patients [6]. When the 
results were analyzed in relation to HLA-DR matching there 
was a significant beneficial effect of blood transfusion except 
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where none of the donor HLA-DR antigens were foreign to the 
recipient. Further data [31] showed a significant (P < 0.01) 
improvement in one year transplant outcome in transfused 
patients and a higher incidence of severe rejection (a rise in 
creatinine over 4 mg%) in untransfused recipients. Opelz who 
collated the largest body of data stated that 'there can be no 
question that the transfusion effect indeed exists' and suggests 
that to abandon elective transfusion at present would be pre-
mature; he advocated a prospective multicenter trial [2J. Such a 
trial should examine not only crude survival data but also the 
number of rejection episodes requiring expensive treatment and 
an increased hospital stay. It remains prudent, therefore, to 
determine ways of preserving the possible benefits of transfu-
sion while preventing sensitization in those awaiting transplan-
tation. 
We have previously demonstrated in a rat model [18J that 
cyclosporin A could diminish but not abolish the primary IgM 
response to blood transfusions; the switch to IgG production, 
however, was completely abrogated. The results of the animal 
study and the present clinical study are therefore broadly 
similar. 
Cyclosporin A acts not only on T lymphocyte responses [17, 
32J but can also affect B cells directly {33]. B lymphocyte 
activation can be achieved by either a T cell independent or 
dependent mechanism. The response to a T dependent antigen 
depends on the production of lymphokines by activated T 
helper lymphocytes. These lymphokines are essential for the 
proliferation and differentiation of B lymphocytes into antibody 
secreting cells [34J. Cyclosporin A modifies the activation and 
abrogates the proliferation of T helper cells; the secretion of T 
cell derived cytokines, including interleukin 2, which influence 
the humoral response is thus diminished [35]. 
In neonatal and adult mice thymectomy alters the IgG but not 
the IgM response to H-2 antigens [36], suggesting that the IgM 
response to histocompatibility antigens is T cell independent. 
Furthermore, IgM production from T cell-depleted, EB virus-
stimulated human lymphocytes in vitro is not affected by 
cyclosporin A, whereas the development of an IgG response is 
inhibited [37J. Although we are cautious about extrapolation 
from experimental studies, these results may explain why 
cyclosporin A did not suppress the IgM response to blood 
transfusions in three of our patients. A primary IgG response is 
highly dependent upon T helper cells, in particular the T 
cell-derived cytokine interleukin 4, which inhibits the produc-
tion of IgM and promotes the switch from IgM to IgG 1 
production [38J. Cyclosporin A blocks the production of inter-
leukin 4 [39], which may explain the suppression of the anti-
body switch in patients in the present study receiving cyclo-
sporin A along with transfusions. 
One patient previously known to have IgG red cell antibodies 
in group 2 developed IgG antibodies after the first transfusion. 
Lymphocyte binding activity was removed by absorption of the 
serum with red cells, suggesting that it was due to cross 
reactivity of the red cell autoantibodies with lymphocytes. 
Although our primary aim was to determine the effect of 
cyclosporin A given with transfusion on the isotype of antibod-
ies produced, we also noted the outcome in the small number of 
patients who received a transplant. All of those who received 
transfusions alone had grafts which failed in less than two 
months and most showed IgG activity against panel lympho-
cytes. The grafts of those given cyclosporin A with transfu-
sions, however, are all functioning at least two years later and 
one patient developed IgM activity during the study period. It 
would be valuable to confirm these results in a larger study. 
Scornik and his colleagues have demonstrated that IgG 
antibodies detected using flow cytometry are associated with a 
high risk of developing cytotoxic antibodies after further blood 
transfusions [24J. They therefore may be an early indicator of 
sensitization. Such antibodies when present against donor 
lymphocytes are associated with prolonged primary graft dys-
function, a greater number of rejection episodes requiring 
treatment with additional therapy including OKT3 and ATG, 
and a higher creatinine level three months after transplantation 
[25, 26J. Furthermore a positive crossmatch detected using flow 
cytometry is associated with poor graft outcome in patients 
with preformed cytotoxic antibodies (PRA > 10%) [6] and in 
those receiving a second or subsequent graft [27, 28]. 
The relevance of IgM antibodies, however, is less clear. 
Several studies have demonstrated that successful renal trans-
plantation can be performed across a positive crossmatch due 
to cytotoxic IgM antibodies [21-23] even if they are alloreac-
tive; the significance of IgM antibodies against donor lympho-
cytes detected only using flow cytometry, however, is un-
known. Clearly many factors influence the ultimate fate of a 
transplant, but our results taken together with evidence from 
the literature may indicate that IgG antibodies were detected 
using flow cytometry or even graft failure. The presence of IgM 
antibodies, however, appears to have little influence on graft 
outcome. 
In conclusion, we have shown that cyclosporin A can abro-
gate the switch from IgM to IgG antibody production in patients 
receiving third-party blood transfusions. The administration of 
cyclosporin A with blood transfusions may prevent the forma-
tion of antibodies which are associated both with development 
of sensitization and subsequent impaired graft function. 
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